Matthias Ferdinand Herdemann

Title: Matthias Ferdinand Herdemann: Innovator in Pharmaceutical Chemistry

Introduction

Matthias Ferdinand Herdemann is a notable inventor based in Reims, France. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target hormone-related conditions. His work is essential in advancing treatments for various cancers.

Latest Patents

Herdemann holds a patent for "Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (GnRH) for use in the treatment of sex hormone related conditions, such as prostatic or uterine cancer." This invention relates to a group of novel pyrazole compounds that are useful as gonadotrophin releasing hormone antagonists. The patent also covers pharmaceutical formulations of these compounds, methods of treatment using them, and processes for their preparation. He has 1 patent to his name.

Career Highlights

Herdemann is associated with AstraZeneca AB, a leading global biopharmaceutical company. His role at AstraZeneca has allowed him to contribute to innovative research and development in the pharmaceutical sector. His expertise in chemistry and pharmacology has been instrumental in the advancement of new therapeutic options.

Collaborations

Throughout his career, Herdemann has collaborated with talented professionals, including Mickael Louis Pierre Maudet and Thomas Geoffrey Colerick Bird. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their respective fields.

Conclusion

Matthias Ferdinand Herdemann is a distinguished inventor whose work in pharmaceutical chemistry has the potential to impact the treatment of hormone-related conditions significantly. His contributions to the field are invaluable, and his ongoing research continues to pave the way for future innovations.